<DOC>
	<DOCNO>NCT00096005</DOCNO>
	<brief_summary>This phase I trial study side effect best dose give tanespimycin together bortezomib treat patient advance solid tumor lymphomas . ( Accrual lymphoma patient close 11/27/09 ) Drugs use chemotherapy , tanespimycin , work different way stop cancer cell divide stop grow die . Bortezomib may stop growth cancer cell block enzymes necessary growth . It may also increase effectiveness tanespimycin make cancer cell sensitive drug . Combining tanespimycin bortezomib may kill cancer cell .</brief_summary>
	<brief_title>Tanespimycin Bortezomib Treating Patients With Advanced Solid Tumors Lymphomas</brief_title>
	<detailed_description>OBJECTIVES : I . Determine dose-limiting toxicity maximum tolerate dose 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) ( tanespimycin ) bortezomib patient advance solid tumor lymphomas ( Accrual Lymphoma Patients Closed 11/27/09 ) . II . Determine change biomarkers ( e.g. , HSP70 , client protein , ubiquitination protein ) peripheral blood mononuclear cell tumor specimens patient advance solid tumor lymphomas ( Accrual Lymphoma Patients Closed 11/27/09 ) treat regimen . III . Determine responses patient treated regimen . IV . Determine toxic effect regimen patient . OUTLINE : This dose-escalation , multicenter study . Patients receive tanespimycin intravenously ( IV ) 1-2 hour bortezomib IV 3-5 second day 1 , 4 , 8 , 11 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos tanespimycin bortezomib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , least 12 additional patient treat above* MTD . NOTE : *Bortezomib administer day 1 course 1 . Patients follow 3 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histologically confirm solid tumor lymphoma ( Accrual Lymphoma Patients Closed 11/27/09 ) Refractory standard treatment OR standard treatment potentially curative capable prolong life expectancy exist Tumor amenable biopsy ( patient accrue MTD ) No CNS metastases Performance status ECOG 02 At least 12 week Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9.0 g/dL Bilirubin ≤ 2 time upper limit normal ( ULN ) AST ≤ 2.5 time ULN Alkaline phosphatase ≤ 2 time ULN ( 5 time ULN due liver involvement ) Creatinine ≤ 2 time ULN QTc &lt; 500 msec men ( 470 msec woman ) LVEF &gt; 40 % echocardiogram Ejection fraction normal echocardiogram ( patient receive prior anthracycline therapy ) No cardiac symptom ≥ grade 2 No New York Heart Association class III IV heart failure No myocardial infarction within past year No active ischemic heart disease within past year No congenital long QT syndrome No leave bundle branch block No history uncontrolled dysrhythmias require antiarrhythmic drug No history cardiac toxicity receive anthracyclines ( e.g. , doxorubicin hydrochloride , daunorubicin hydrochloride , mitoxantrone hydrochloride , bleomycin , carmustine ) No poorly control angina No history serious ventricular arrhythmia ( ventricular tachycardia ventricular fibrillation ≥ 3 beat row ) No significant cardiac disease Pulse oximetry rest exercise &lt; 88 % ( per Medicare guideline ) No pulmonary symptom ≥ grade 2 No significant pulmonary disease require oxygen supplementation cause severe limitation activity No symptomatic pulmonary disease require medication include follow : Dyspnea exertion Paroxysmal nocturnal dyspnea Oxygen requirement significant pulmonary disease , include chronic obstructive/restrictive pulmonary disease No home oxygen use meet Medicare criteria No history pulmonary toxicity receive anthracyclines ( e.g. , doxorubicin hydrochloride , daunorubicin hydrochloride , mitoxantrone hydrochloride , bleomycin , carmustine ) No seizure disorder No sensory peripheral neuropathy &gt; grade 1 No neuropathic pain etiology Patients residual peripheral neuropathy ≤ grade 1 due oxaliplatin therapy allow No uncontrolled infection No prior serious allergic reaction egg Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Willing return Mayo Clinic Rochester , Mayo Clinic Arizona , Mayo Clinic Florida follow More 4 week since prior immunotherapy biologic therapy No concurrent prophylactic colonystimulating factor No concurrent immunotherapy , biologic therapy , gene therapy More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) No concurrent chemotherapy Concurrent steroid ( stable dose ≥ 4 week ) comorbid condition ( e.g. , adrenal insufficiency rheumatoid arthritis ) allow More 4 week since prior radiotherapy No prior radiotherapy potentially included heart field ( e.g. , mantle ) chest No prior radiotherapy &gt; 25 % bone marrow No prior radiopharmaceutical No concurrent radiotherapy Recovered prior therapy More 8 week since prior UCN01 No concurrent warfarin Low molecular weight heparin allow No concurrent medication prolong may prolong QTc interval No concurrent investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>